UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.